Media
Displaying 1 - 10 of 61
Santen today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea® (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the…
Osaka, Japan – Following European Commission approval on June 2, Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced that Ryjunea® is now available in Germany. Germany is the first…
June 5, 2025 – Osaka, Japan – Santen today announced that the European Commission has granted market authorization for Santen’s RYJUNEA®, a low-dose atropine eye drop (0.1 mg/ml), that slows the…
Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive…
Results newly published in the peer-review journal, Graefe’s Archive for Clinical and Experimental Ophthalmology, from the MERCURY-3 trial support the addition of Roclanda® as an alternative fixed-…
Geneva, Switzerland – Santen, a global specialist in ophthalmology, will share new long-term data on PRESERFLO® MicroShunt at the World Glaucoma Congress (WGC) – taking place in Rome, Italy from…
Geneva, Switzerland – Santen, a global specialist in ophthalmology, is delighted to present ‘Pioneers in glaucoma: A history of ground-breaking progress’, an interactive timeline mapping the people…
Santen Pharmaceutical Co., Ltd. (head Office in Osaka City; hereinafter “Santen”) today announced European Medicines Agency (EMA) acceptance for review of a marketing authorization application for…
Santen EMEA is pleased to announce the results of PERSPECTIVE, a real-world evidence study evaluating the long-term treatment of severe keratitis in adult dry eye disease (DED) patients.
Santen, in partnership with UCL Institute of Ophthalmology (IoO), is proud to announce the company’s first external research laboratory in Europe.
